PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 17, 2026The Brazilian Journal of Infectious Diseases0 citationsOpen Access

PLGA Nanoparticles Improve Rifampicin Efficacy Against Mycobacterium Tuberculosis

Development, Characterization, and in Vitro Evaluation of Plga 50:50 Nanoparticles Against a Mycobacterium Tuberculosis Strain

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLuanna de Ângelis Correia de SousaAPAna Lúcia Figueiredo PortoGRGiovanna Gabriela Pedroza Rodrigues

Discussion

Loading...

Member takes

Overview

Demonstrates enhanced antimycobacterial activity of PLGA nanoparticles containing rifampicin against Mycobacterium tuberculosis, suggesting a promising treatment alternative.

Key Points

  • The study aims to develop a PLGA nanoformulation of rifampicin and assess its efficacy against Mycobacterium tuberculosis.
  • Developed PLGA 50:50 nanoparticles using the single-emulsion method
  • Characterized nanoparticles for size, polydispersity index, zeta potential, and encapsulation efficiency
  • Evaluated in vitro antimycobacterial activity against Mycobacterium tuberculosis strain H37Ra
  • Used microdilution and resazurin for activity assessment
  • N-PLGA50:50-RIF nanoparticles had a mean diameter of 220.9 nm and an encapsulation efficiency of 18%
  • Demonstrated an MIC of 0.031 µg/mL, significantly lower than the 0.250 µg/mL for free rifampicin
  • Showed approximately eight times greater inhibition potential compared to free rifampicin

Cite This Study

Sousa et al. (2026) studied this question.

synapsesocial.com/papers/69b8ef36deb47d591b8c5491https://doi.org/10.1016/j.bjid.2026.105677
View Full Paper
Ask AI
Bookmark
Share